

Newsletter

Inflammatory Bowel Disease and Functional Bowel Disorders Review Group

Editorial Team

Brian Feagan
(Coordinating Editor)
Canada

John WD McDonald
Canada

Lloyd Sutherland
Canada

Jorgen Rask-Madsen
Denmark

John Marshall
Canada

Tony Akobeng UK

Philip Schoenfeld USA

Nilesh Chande
Canada

John K MacDonald
Managing Editor
Canada

Beverly Jasevicius
Trial Search Coordinator

Cochrane IBD/FBD Group
Robarts Clinical Trials
London ON Canada

Tel: 1 519 931 5700 x24763
Fax: 1 519 931 5705
jmacdon1@uwo.ca
www.cochrane.uottawa.ca/ibd

Update on Publication


As of Issue 4, 2011 (publication date 13 April 2011) [the Cochrane IBD/FBD group](#) will have a total of 60 reviews and 30 protocols published in the Cochrane Library. We would like to take this opportunity to thank the many individuals involved in producing these high quality systematic reviews.

Welcome New Editor

We are pleased to announce that Dr Philip Schoenfeld (University of Michigan School of Medicine, Ann Arbor, MI, USA) has agreed to serve as an Editor for the Cochrane IBD/FBD group. Dr Schoenfeld is an internationally recognized expert in the therapy of functional bowel disorders including irritable bowel syndrome. He is currently the Director of the Training Program in GI Epidemiology and Associate Professor of Medicine at the University of Michigan School of Medicine. We would like to take this opportunity to welcome Phil in his new role as Editor and we look forward to working with him in this capacity.

Thank you to Outgoing Editor

In June 2010 Dr Nicholas Talley moved on to a new position as Pro Vice Chancellor of the Faculty of Health at the University of Newcastle, New South Wales, Australia. We would like to take this opportunity to thank Dr Talley for his contributions to the Cochrane IBD/FBD group.



**THE COCHRANE
COLLABORATION®**

High Impact Factor


The publisher of the Cochrane Library, (Wiley-Blackwell) regularly assesses the impact of the Cochrane Database of Systematic Reviews (CDSR) and the impact of each review group that prepares systematic reviews for inclusion in the Cochrane Library. In 2009 an Impact Factor of 5.653 was calculated for the CDSR. The Impact Factor for the IBD/FBD review group in 2009 was calculated to be 8.609.

CRG	Category (median IF)	Top Journal by IF	Possible match from subject
Inflammatory Bowel Disease and Functional Bowel Disorder Group	Gastroenterology and Hepatology	Gastroenterology	Inflammatory Bowel Diseases
8.609	2.092	12.899	4.613

The IBD/FBD group had the 4th highest Impact Factor out of 50 Cochrane review groups worldwide in 2009 and has the highest Impact Factor for review groups based in Canada. Our Impact Factor compares very favorably with other journals in

our area including: The Canadian Journal of Gastroenterology (IF for 2009 was 2.0), Inflammatory Bowel Diseases (IF 4.6), The American Journal of Gastroenterology (IF 6.1) and Gastroenterology (IF 12.9).

Impact Factor for each CRG (# of cites in 2009 to reviews published in 2007-2008, divided by the number of reviews published in 2007-2008)



RevMan 5.1

We are pleased to announce the release of RevMan 5.1. The new version has been developed in response to feedback from authors and other users. We encourage all authors to update to the new version of RevMan. To update, please accept the automatic update prompt when you next open RevMan - the updating process will only take a few minutes. There are several reasons why we would encourage you and your review teams to update:

- The update includes many new improved features that will make

it easier for you to complete your review, see <http://ims.cochrane.org/revman/new-releases/whats-new-in-revman-5> for details.

- There are modifications and improvements to the Risk of Bias tool in RevMan 5.1, which can only be viewed in RevMan 5.1.
- Using the same version as the editorial base of your Review Group will ease the process of submitting new or updated reviews for publication. To help you understand the changes to the Risk of Bias tool for RevMan 5.1

and the implications for your existing reviews as well as new and updated reviews, please read the document at: <http://ims.cochrane.org/revman/documentation/Risk-of-bias-in-RevMan-5.1.pdf>.

You will find other updated support materials in the RevMan 5.1 Help menu, such as the Handbook, RevMan User Guide and tutorials. The new version 5.1.0 of the Cochrane Handbook for Systematic Reviews of Interventions is also available online at <http://www.cochrane.org/training/cochrane-handbook>.



Cochrane Symposium at Digestive Disease Week 2011

“Controversies and Consensus: How Cochrane Reviews Guide Therapy in Inflammatory Bowel Disease”

Brian G Feagan, Chair

DDW 2011 Chicago IL USA
May 9, 2011 from 4 to 5:30 pm
Location S100AB (MCP)

Participants will:

- Review the principles and importance of systematic reviews
- Discuss how controversies regarding therapy are resolved by data synthesis
- Discuss how systematic reviews can influence the management of patients with IBD

Presentations:

- Induction of Remission in Crohn's Disease: a Synthesis of Data from Cochrane Reviews
John W. McDonald, MD, PhD, FRCPC
- Maintenance of Remission in Crohn's Disease: a Synthesis of Data from Cochrane Reviews
Anthony K. Akobeng, MD, FRCPCH
- An Evidence-based Treatment Algorithm for Crohn's Disease
Nilesh Chande, MD, FRCPC
- Induction of Remission in Ulcerative Colitis: a Synthesis of Data from Cochrane Reviews
John K. Marshall, MD
- Maintenance of Remission in Ulcerative Colitis: a Synthesis of Data from Cochrane Reviews
Antje Timmer, MD, MSc, PhD
- An Evidence-based Treatment Algorithm for Ulcerative Colitis
Corey A. Siegel, MD

Sponsored By: The Cochrane Collaboration, Clinical Practice, Immunology, Microbiology & Inflammatory Bowel Diseases